USSTOCK.TODAY
Pre-Market
Log in Sign up

Moderna transitions from COVID vaccines to cancer therapeutics

The Motley Fool +1 ·

MRNA Moderna Inc
$242.08 +6.69%
View chart & analysis →
  1. 1Moderna recorded sales of over $18 billion during its 2022 vaccine peak.
  2. 2Moderna is testing its personalized cancer vaccine, Intismeran Autogen, in 10 clinical trials.
  3. 3Moderna is attracting market attention with a stock price increase of over 600% this year.

So what's the key point?

Moderna is focusing on developing cancer treatments beyond COVID vaccines. The company's stock price has risen by more than 600% this year as it conducts cancer vaccine trials.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Moderna joins Nasdaq 100 index and sees 700% stock surge this year The Motley Fool +1 · 2d agoMerck CEO expects accelerated production of cancer vaccines in collaboration with Moderna CNBC · 6d agoModerna stock rises more than 600% this year Quartz · Oct 13
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news